在牛皮中使用certollizumab pegol的概述,包括结构特征,药理动力学和治疗方法
Michio Tokuyama1, Tomotaka Mabuchi1
1Department of Dermatology, Tokai University School of Medicine, Isehara, Kanagawa, 2591193, Japan.
Immunotherapy
|February 6, 2024
概括
作为TNF-α抑制剂的 Certolizumab pegol (CZP) 为治疗牛皮,特别是孕妇提供了独特的安全性. 它的疗效和安全性与其他TNF-α抑制剂相当.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮病的发病包括关键的细胞因子,如瘤坏死因子-α (TNF-α),联素-23 (IL-23) 和联素-17 (IL-17).
- 针对这些细胞因子的生物疗法在治疗牛皮方面表现出显著的有效性.
- 有几种TNF-α抑制剂可用,包括因弗利西玛布,阿达利穆马布,伊坦塞普特,戈利穆马布和克尔科利祖马布佩戈尔 (CZP).
研究的目的:
- 为了突出Certolizumab pegol (CZP) 在治疗牛皮的TNF-α抑制剂中独特的结构和机制特性.
- 评估CZP的安全性和有效性概况,特别是其适用于孕妇的适用性以及其长期作用的潜力.
主要方法:
- 对临床试验数据和CZP的药理性质的审查.
- 与其他可用的TNF-α抑制剂治疗牛皮的疗效和安全性的比较.
- 分析CZP的独特结构 (缺乏Fc区域,PEGylation) 以及其影响.
主要成果:
- 由于CZP缺乏Fc区域,可以防止胎盘转移,使孕妇可以安全使用.
- CZP的PEGylation可能导致扩大组织分布和潜在的更持久的治疗效果.
- 临床试验表明,CZP在治疗牛皮的皮肤和关节症状方面的疗效与其他TNF-α抑制剂相当.
- 在CZP与其他TNF-α抑制剂之间没有观察到安全性概况的显著差异.
结论:
- 塞尔科利祖马布佩戈尔 (CZP) 对于牛皮是一种有价值的治疗选择,为孕妇患者提供明显的安全优势.
- CZP的独特结构属性有助于其有利的安全性和在治疗牛皮的潜在持续有效性.
- CZP的疗效和安全性与现有的TNF-α抑制剂相当,扩大了牛皮患者的治疗选择.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525


